Strategic Partnerships Aptar Digital Health already collaborates with Enable Injections, ŌURA, Biogen, SHL Medical, and AstraZeneca on digital health initiatives. This network creates cross sell opportunities to bring Aptar’s end to end platform to pharma and device partners for patient engagement, onboarding, data analytics, and connected delivery. Propose joint sales of enFuse self injection or Migraine Buddy with AI screening and wearables to improve adherence and outcomes.

AI Analytics The tech stack including TensorFlow and Azure supports AI powered screening, predictive analytics, and personalized patient interventions. A licensing partnership with AstraZeneca demonstrates appetite for AI in neurological and rare disease care. Target Biogen and AstraZeneca for enterprise analytics, remote monitoring, and real world evidence generation; emphasize secure data handling and scalable cloud architecture.

Delivery Edge Strength in connected drug delivery and self injection with SHL Medical alignment; this opens upsell to additional self injectables and neurology portfolios. Propose bundled solutions pairing delivery hardware with software patient journey tools to improve administration efficiency and adherence.

Growth Readiness As part of AptarGroup, Digital Health can leverage global scale to reach large pharma and medtech customers beyond its current size. Use partnerships like Biogen and AstraZeneca as anchor deals to expand geographic footprint in US and Europe, and to integrate QoL migraine research collaboration for evidentiary pilots.

Patient ROI The portfolio is designed to boost patient experience and outcomes through mobile and web apps, onboarding, training and analytics. Frame ROI for payers and providers around adherence, reduced waste, and improved treatment journeys; cite migraine and neurological disease use cases; propose pilots with QoL lab collaboration to generate data driven results.